Novan Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
112.00
-
-
2,140.00
5,991
Cost of Goods Sold (COGS) incl. D&A
-
631.00
757.00
-
-
Gross Income
-
631.00
757.00
-
-
SG&A Expense
11,478.00
25,203.00
59,069.00
36,678.00
32,556
EBIT
11,828.00
25,834.00
59,826.00
35,961.00
28,229
Unusual Expense
641.00
-
-
224.00
16,234
Non Operating Income/Expense
9.00
1.00
48.00
102.00
72
Interest Expense
701.00
1.00
2.00
1,044.00
1,047
Pretax Income
13,103.00
25,786.00
59,699.00
37,127.00
12,673
Consolidated Net Income
13,103.00
25,786.00
59,699.00
37,127.00
12,673
Net Income
13,103.00
25,786.00
59,699.00
37,127.00
12,673
Net Income After Extraordinaries
14,818.00
23,512.00
59,699.00
37,127.00
12,673
Net Income Available to Common
11,388.00
28,060.00
59,699.00
37,127.00
12,673
EPS (Basic)
0.71
1.76
9.97
2.32
0.49
Basic Shares Outstanding
15,938.70
15,938.70
5,986.00
15,981.20
25,795.70
EPS (Diluted)
0.71
1.76
9.97
2.32
0.49
Diluted Shares Outstanding
15,938.70
15,938.70
5,986.00
15,981.20
25,795.70
EBITDA
11,366.00
25,203.00
59,069.00
34,538.00
26,565
Non-Operating Interest Income
58.00
48.00
81.00
-
297

About Novan

View Profile
Address
4105 Hopson Road
Morrisville North Carolina 27560
United States
Employees -
Website http://www.novan.com
Updated 07/08/2019
Novan, Inc. is a biotechnology company which uses nitric oxide-based technology to develop product candidates. It focuses on nitric oxide's natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Morrisville, NC.